Linghua Wang, M.D., Ph.D.

Assistant Professor, Department of Molecular and Human Genetics

image: Linghua Wang, M.D., Ph.D.Contact information


Postdoc, Baylor College of Medicine, 2012

Ph.D., The University of Tokyo, 2011

M.D., Sun Yat-Sen University, 2006

B.S., Taishan Medical University, 2003

Awards and Honors

2011: Chinese Government Award for Outstanding Students Abroad
         Awarding Institute: China Scholarship Council
         Sponsor: Chinese Ministry of Education
         Winner: 495 PhD students from 275 universities of 25 countries worldwide

Research Interests

My primary interests are to advance the scientific understanding of human cancers through next-generation sequencing technologies and to explore new treatment possibilities for patients suffering from these diseases. I am currently leading the genomic data analysis of rare cancers for which little is currently known.

A large proportion of common cancers affecting patients around the world have been selected for comprehensive cancer genome studies. Further efforts will be needed to tackle the remaining tumor types, including the rare forms of cancers. Although rare, these cancers tend to be more aggressive and fast growing with an early recurrence following initial chemotherapy and poor prognosis. Besides, patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer. While sample collection is a major challenge, the integrated genomic analyses would identify novel causative genes in these rare cancers, shed new light on the biology of the rare cancers, as well as guide novel targeted cancer therapies. Through efficient collaboration, the Cancer Genomics Group at the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has collected/is expected to collect 20 different types of rare cancers, 15-30 cases each. Whole-exome sequencing and high-resolution SNP array analysis were/will be performed for all cases and whole-genome sequencing or mRNA sequencing was designed for a selected subset of the cases.


Eckstein OS, Wang L, Punia JN, et al. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol. 2016;44(8):740-4. doi:10.1016/j.exphem.2016.05.003.

Wang L, Wheeler DA, Prchal JT. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol. 2016;44(8):644-52. doi:10.1016/j.exphem.2015.11.005.

Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007-15. doi:10.1182/blood-2014-05-577825.

Wang L, Yamaguchi S, Burstein MD, et al. Novel somatic and germline mutations in intracranial germ cell tumours. Nature. 2014;511(7508):241-5. doi:10.1038/nature13296.

Arai E, Sakamoto H, Ichikawa H, et al. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer. 2014;135(6):1330-42. doi:10.1002/ijc.28768.

Wang L, Wheeler DA. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med. 2014;65:33-48. doi:10.1146/annurev-med-120811-171056.

Wheeler DA, Wang L. From human genome to cancer genome: the first decade. Genome Res. 2013;23(7):1054-62. doi:10.1101/gr.157602.113.

Ikeda Y, Oda K, Nakagawa S, et al. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer. 2012;22(5):725-31. doi:10.1097/IGC.0b013e31824c6ea6.